Biohaven Ltd. received a partial clinical hold from the FDA on September 4, 2026, pausing new patient enrollment in its BHV-7000 program for refractory focal epilepsy due to insufficient nonclinical data regarding a specific metabolite observed in rodent testing. The hold applies only to new enrollment; dosing continues for over 600 already randomized patients across the program. Study BHV7000-303 is fully enrolled, with topline data expected in the second half of 2026. On August 26, 2026, Biohaven Bioscience Ireland Limited entered into a license agreement with SK Biopharmaceuticals Co., Ltd., granting an exclusive, royalty-bearing worldwide license to its Kv7 ion channel platform, including BHV-7000, pending HSR clearance. The company operates in the biotechnology industry, focusing on developing treatments for neurological disorders.
